125 related articles for article (PubMed ID: 28918548)
1. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
Connolly RM; Fackler MJ; Zhang Z; Zhou XC; Goetz MP; Boughey JC; Walsh B; Carpenter JT; Storniolo AM; Watkins SP; Gabrielson EW; Stearns V; Sukumar S
Breast Cancer Res Treat; 2018 Jan; 167(1):107-116. PubMed ID: 28918548
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
3. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Tu Y; Hershman DL; Bhalla K; Fiskus W; Pellegrino CM; Andreopoulou E; Makower D; Kalinsky K; Fehn K; Fineberg S; Negassa A; Montgomery LL; Wiechmann LS; Alpaugh RK; Huang M; Sparano JA
Breast Cancer Res Treat; 2014 Jul; 146(1):145-52. PubMed ID: 24903226
[TBL] [Abstract][Full Text] [Related]
5. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
Fackler MJ; Lopez Bujanda Z; Umbricht C; Teo WW; Cho S; Zhang Z; Visvanathan K; Jeter S; Argani P; Wang C; Lyman JP; de Brot M; Ingle JN; Boughey J; McGuire K; King TA; Carey LA; Cope L; Wolff AC; Sukumar S
Cancer Res; 2014 Apr; 74(8):2160-70. PubMed ID: 24737128
[TBL] [Abstract][Full Text] [Related]
6. Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.
Stearns V; Fackler MJ; Hafeez S; Bujanda ZL; Chatterton RT; Jacobs LK; Khouri NF; Ivancic D; Kenney K; Shehata C; Jeter SC; Wolfman JA; Zalles CM; Huang P; Khan SA; Sukumar S
Cancer Prev Res (Phila); 2016 Aug; 9(8):673-682. PubMed ID: 27261491
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
[TBL] [Abstract][Full Text] [Related]
8. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
9. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
10. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.
Matsui S; Kagara N; Mishima C; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Oct; 36(4):2225-35. PubMed ID: 27499429
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
Fujii S; Yamashita S; Yamaguchi T; Takahashi M; Hozumi Y; Ushijima T; Mukai H
Oncotarget; 2017 Mar; 8(12):19039-19048. PubMed ID: 28186977
[TBL] [Abstract][Full Text] [Related]
16. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
18. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
Gampenrieder SP; Rinnerthaler G; Hackl H; Pulverer W; Weinhaeusel A; Ilic S; Hufnagl C; Hauser-Kronberger C; Egle A; Risch A; Greil R
Theranostics; 2018; 8(8):2278-2288. PubMed ID: 29721079
[No Abstract] [Full Text] [Related]
20. [Dynamics of LINE-1 Retrotransposon Methylation Levels in Circulating DNA from Lung Cancer Patients Undergoing Antitumor Therapy].
Ponomaryova AA; Cherdyntseva NV; Bondar AA; Dobrodeev AY; Zavyalov AA; Tuzikov SA; Vlassov VV; Choinzonov EL; Laktionov PP; Rykova EY
Mol Biol (Mosk); 2017; 51(4):622-628. PubMed ID: 28900080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
